Assessing the MGMT status in glioblastoma: One step forward, two steps back?

Neuro-Oncology

Volumn 15, Issue 3, 2013, Pages 253-254

  Weller, Michael ^a  

^a EANO ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CARMUSTINE; CILENGITIDE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NITROSOUREA; PLATINUM; TEMOZOLOMIDE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DNA METHYLATION; EDITORIAL; ENZYME ACTIVITY; GLIOBLASTOMA; HUMAN; IMMUNOCHEMISTRY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; SURVIVAL TIME;

BRAIN NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; MALE; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84874522500     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not014     Document Type: Editorial

References (9)

1. Jaeckle KA, Eyre HJ, Townsend JJ, et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol. 1998;16:3310-3315. (Pubitemid 28481626)
2. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350-1354.
3. Hegi ME, Diserens AC, Gorlia T, et al.MGMTgene silencing and response to temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003. (Pubitemid 40349502)
4. Weller M, Stupp R, Reifenberger G, Brandes AA, Van den Bent MJ, Wick W, Hegi ME. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nature Rev Neurol. 2010;6:39-51.
5. Preusser M, Janzer RC, Felsberg J, et al. Anti-O6- methylguaninemethyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol. 2008;18:520-532.
6. Wick W, Platten M, Meisner C, et al. Chemotherapy versus radiotherapy for malignant astrocytoma in the elderly. Lancet Oncol. 2012;13:707-715.
7. Malmström A, Grønberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy for patients aged over 60 years with glioblastoma: the Nordic randomized phase 3 trial. Lancet Oncol. 2012;13: 916-926.
8. Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing in malignant glioma patients in clinical practice. Neuro Oncol. 2012; 14:iv100-iv108
9. Lalezari S, Chou AP, Tran, et al. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro Oncol. 2013;15: 370-381.